Skip to main content

Advertisement

Fig. 3 | Cell & Bioscience

Fig. 3

From: Co-administration with DNA encoding papillomavirus capsid proteins enhances the antitumor effects generated by therapeutic HPV DNA vaccination

Fig. 3

Characterization of BPV1 and HPV-16 L1 or L2-specific CD4+ T cell immune responses generated by CRT/E7 or OVA DNA mixed with DNA encoding BPV1 or HPV-16 L1 or L2. C57BL/6 mice (five per group) were vaccinated intradermally via gene gun with 2 μg/mouse of CRT/E7 with or without BPV1 or HPV-16 L1 or L2 DNA twice at 1-week intervals. Splenocytes from vaccinated mice were collected 1 week after last immunization and pulsed with 5 μg/mL of BPV1 or HPV-16 L1/L2 VLPs. The BPV1 L1/ L2-specific CD4+ T cell immune responses were characterized using intracellular cytokine staining followed by flow cytometry analysis. a Representative flow cytometry data depicting the number of BPV1 L1/L2-specific CD4+ T cells. b Bar graph representing the number of BPV1 L1/L2-specific CD4+ T cells/3x105 splenocytes (mean± SD). c Representative flow cytometry data depicting the number of HPV-16 L1/L2-specific CD4+ T cells. d Bar graph representing the number of HPV-16 L1/L2-specific CD4+ T cells/3x105 splenocytes (mean± SD). Data shown are representative of two experiments performed. * indicates p < 0.05

Back to article page